145 related articles for article (PubMed ID: 28362710)
1. Detection of Loss of Heterozygosity (LOH) Using Circulating Cell-free DNA (cfDNA) by Fluorescence-based Multiplex PCR for Identification of Patients With Prostate Cancer.
Seyedolmohadessin SM; Akbari MT; Nourmohammadi Z; Basiri A; Pourmand G
Appl Immunohistochem Mol Morphol; 2018; 26(10):749-759. PubMed ID: 28362710
[TBL] [Abstract][Full Text] [Related]
2. Comparison of genetic alterations detected in circulating microsatellite DNA in blood plasma samples of patients with prostate cancer and benign prostatic hyperplasia.
Müller I; Urban K; Pantel K; Schwarzenbach H
Ann N Y Acad Sci; 2006 Sep; 1075():222-9. PubMed ID: 17108215
[TBL] [Abstract][Full Text] [Related]
3. Identification of loss of heterozygosity on circulating free DNA in peripheral blood of prostate cancer patients: potential and technical improvements.
Müller I; Beeger C; Alix-Panabières C; Rebillard X; Pantel K; Schwarzenbach H
Clin Chem; 2008 Apr; 54(4):688-96. PubMed ID: 18281424
[TBL] [Abstract][Full Text] [Related]
4. Detection of tumor-specific DNA in blood and bone marrow plasma from patients with prostate cancer.
Schwarzenbach H; Chun FK; Lange I; Carpenter S; Gottberg M; Erbersdobler A; Friedrich MG; Huland H; Pantel K
Int J Cancer; 2007 Apr; 120(7):1465-71. PubMed ID: 17205532
[TBL] [Abstract][Full Text] [Related]
5. Microsatellite analysis of allelic imbalance in tumour and blood from patients with prostate cancer.
Schwarzenbach H; Chun FK; Müller I; Seidel C; Urban K; Erbersdobler A; Huland H; Pantel K; Friedrich MG
BJU Int; 2008 Jul; 102(2):253-8. PubMed ID: 18336598
[TBL] [Abstract][Full Text] [Related]
6. Quick assessment of cell-free DNA in seminal fluid and fragment size for early non-invasive prostate cancer diagnosis.
Ponti G; Maccaferri M; Manfredini M; Micali S; Torricelli F; Milandri R; Del Prete C; Ciarrocchi A; Ruini C; Benassi L; Bettelli S; Kaleci S; Ozben T; Tomasi A
Clin Chim Acta; 2019 Oct; 497():76-80. PubMed ID: 31301282
[TBL] [Abstract][Full Text] [Related]
7. [Detailed mapping and clinical significance of loss of heterozygosity on 9p13-23 in laryngeal squamous cell carcinoma by microsatellite analysis].
Xu XF; Tang PZ; Cheng SJ
Ai Zheng; 2003 May; 22(5):452-7. PubMed ID: 12753701
[TBL] [Abstract][Full Text] [Related]
8. Loss of heterozygosity and microsatellite instability at chromosomal sites 1Q and 10Q in morphologically distinct regions of late stage prostate lesions.
Latini JM; Rieger-Christ KM; Wang DS; Silverman ML; Libertino JA; Summerhayes IC
J Urol; 2001 Nov; 166(5):1931-6. PubMed ID: 11586263
[TBL] [Abstract][Full Text] [Related]
9. High frequency of deletion on chromosome 9p21 may harbor several tumor-suppressor genes in human prostate cancer.
Perinchery G; Bukurov N; Nakajima K; Chang J; Li LC; Dahiya R
Int J Cancer; 1999 Nov; 83(5):610-4. PubMed ID: 10521795
[TBL] [Abstract][Full Text] [Related]
10. Involvement of the multiple tumor suppressor genes and 12-lipoxygenase in human prostate cancer. Therapeutic implications.
Gao X; Porter AT; Honn KV
Adv Exp Med Biol; 1997; 407():41-53. PubMed ID: 9321930
[TBL] [Abstract][Full Text] [Related]
11. A critical evaluation of loss of heterozygosity detected in tumor tissues, blood serum and bone marrow plasma from patients with breast cancer.
Schwarzenbach H; Müller V; Beeger C; Gottberg M; Stahmann N; Pantel K
Breast Cancer Res; 2007; 9(5):R66. PubMed ID: 17915011
[TBL] [Abstract][Full Text] [Related]
12. Detailed deletion mapping of loss of heterozygosity on 9p13-23 in laryngeal squamous cell carcinoma by microsatellite analysis.
Xu XF; Gao YN; Cheng SJ
Chin Med J (Engl); 2004 Aug; 117(8):1204-9. PubMed ID: 15361296
[TBL] [Abstract][Full Text] [Related]
13. Microsatellite alterations and loss of heterozygosity in Peyronie's disease.
Perinchery G; El-Sakka AI; Angan A; Nakajima K; Dharia A; Tanaka Y; Lue TF; Dahiya R
J Urol; 2000 Sep; 164(3 Pt 1):842-6. PubMed ID: 10953165
[TBL] [Abstract][Full Text] [Related]
14. [Loss of heterozygosity on chromosome 9p13-23 in microdissected laryngeal squamous cell carcinoma by microsatellite analysis].
Xu X; An Q; Zhang J; Tang P; Cheng S
Zhonghua Er Bi Yan Hou Ke Za Zhi; 2001 Oct; 36(5):367-71. PubMed ID: 12761947
[TBL] [Abstract][Full Text] [Related]
15. Loss of heterozygosity for chromosomal regions 15q14-21.1, 17q21.31, and 13q12.3-13.1 and its relevance for prostate cancer.
Nowacka-Zawisza M; Forma E; Walczak M; Różański W; Bryś M; Krajewska WM
Med Oncol; 2015 Nov; 32(11):246. PubMed ID: 26433958
[TBL] [Abstract][Full Text] [Related]
16. Loss of heterozygosity on chromosome 2 in Japanese patients with prostate cancer.
Ueda T; Komiya A; Suzuki H; Shimbo M; Sakamoto S; Imamoto T; Akakura K; Shiraishi T; Ichikawa T
Prostate; 2005 Aug; 64(3):265-71. PubMed ID: 15717310
[TBL] [Abstract][Full Text] [Related]
17. Using Genetic and Epigenetic Markers to Improve Differential Diagnosis of Prostate Cancer and Benign Prostatic Hyperplasia by Noninvasive Methods in Mexican Patients.
Sánchez BE; Aguayo A; Martínez B; Rodríguez F; Marmolejo M; Svyryd Y; Luna L; Muñoz LA; Jiménez MA; Sotomayor M; Vargas V F; Mutchinick OM
Clin Genitourin Cancer; 2018 Aug; 16(4):e867-e877. PubMed ID: 29571584
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic Analysis of Circulating Tumor DNA in Localized and Metastatic Prostate Cancer: Evaluation of Clinical Biomarker Potential.
Bjerre MT; Nørgaard M; Larsen OH; Jensen SØ; Strand SH; Østergren P; Fode M; Fredsøe J; Ulhøi BP; Mortensen MM; Jensen JB; Borre M; Sørensen KD
Cells; 2020 May; 9(6):. PubMed ID: 32486483
[TBL] [Abstract][Full Text] [Related]
19. Evidence for three tumor suppressor loci on chromosome 9p involved in melanoma development.
Pollock PM; Welch J; Hayward NK
Cancer Res; 2001 Feb; 61(3):1154-61. PubMed ID: 11221846
[TBL] [Abstract][Full Text] [Related]
20. Assessing the Diagnostic Value of Plasma-Free DNA in Prostate Cancer Screening.
Seyedolmohadessin SM; Akbari MT; Nourmohammadi Z; Basiri A; Pourmand G
Iran Biomed J; 2018 Sep; 22(5):331-7. PubMed ID: 29475366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
